Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 46.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,301 shares of the medical research company's stock after buying an additional 1,679 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Charles River Laboratories International were worth $987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors also recently bought and sold shares of the company. Wolff Wiese Magana LLC bought a new stake in Charles River Laboratories International in the third quarter worth $32,000. Versant Capital Management Inc increased its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Assetmark Inc. increased its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company's stock worth $37,000 after purchasing an additional 173 shares during the last quarter. Pinnacle Bancorp Inc. increased its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new stake in Charles River Laboratories International in the third quarter worth $59,000. Institutional investors own 98.91% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have commented on CRL shares. TD Cowen lifted their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a "hold" rating in a research note on Monday, November 11th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating for the company in a research note on Monday, February 3rd. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 5th. The Goldman Sachs Group dropped their price objective on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Finally, Bank of America dropped their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a "neutral" rating for the company in a research note on Friday, December 13th. Three analysts have rated the stock with a sell rating, fourteen have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $200.79.
Read Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Stock Down 0.7 %
NYSE:CRL traded down $1.10 during mid-day trading on Friday, reaching $152.07. The company's stock had a trading volume of 841,129 shares, compared to its average volume of 1,002,698. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The stock has a fifty day moving average of $176.43 and a 200-day moving average of $190.73. The firm has a market capitalization of $7.78 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61.
Charles River Laboratories International Profile
(
Free Report)
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Further Reading
Before you consider Charles River Laboratories International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.
While Charles River Laboratories International currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
